Searched for
ALBUTEROL SULFATE
Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...- These healthcare and pharma stocks may deliver more than 20% in one yearCheck out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focu...
- US unit of India's Cipla recalls six batches of bronchospasm inhalerIndian pharmaceutical company Cipla has recalled six batches of its Albuterol Sulfate HFA Inhalation Aerosol in the US due to a container d...
- On a path to recovery; 7 mid-cap pharma stocks with an upside potential up to 47 %After the covid tailwinds got over, pharma stocks witnessed a phase of under-performance. However as the markets get jittery, select pharma...
- Analysts give a thumbs up to Cipla’s Q2 report card, see 30% upside in the stockJefferies was the most optimistic as it maintained its buy rating on the stock, and raised the target price to Rs 1,024 from Rs 914 earlier.
- Pharma sector to remain a market favourite due to earnings visibility, say analystsThe sector will remain a market favourite due to earnings visibility, which does not exist for most sectors currently because of the pandem...
- Cipla, Lupin may gain from Perrigo's drug recall, says MacquariePerrigo announced the voluntary nationwide recall of albuterol sulfate following complaints that some units may not dispense due to cloggin...
- Pharma’s perennial underperformer gets a shot in the arm. Can it deliver?The stock has gained 64 per cent from March lows and 27 per cent year to date, but still 54 per cent down from its all-time high of Rs 2,12...
- Lupin gets US health regulator's approval for asthmatic symptoms prevention drugThe approved product is a generic version of ProAir HFA of Teva Branded Pharmaceutical Products R&D, Inc. In a regulatory filing, Lupin sai...
- Lupin trades above Rs 1,000 for the first time since Nov 2017The pharma major last week reported a 64.72 per cent decline in its consolidated net profit to Rs 106.90 crore for the quarter to June 2020...
- Buy Cipla, target price Rs 668: ICICI SecuritiesThe brokerage has raised FY21-FY22 EPS estimates by 11-12 per cent on generic Proventil approval and the increase in Rs/$ rate to 74 from 7...
- The Week That Was in 10 Stocks: Pharma shares on a tear; IDBI, IndusInd Bank rallyA second stimulus package India is poised to announce in coming days will be worth around Rs 1 lakh crore.
- Market Movers: M&M, Maruti, Cipla soar; 19 stocks turn ‘overbought’As many as 19 stocks turned ‘overbought’ as they crossed the 70 mark on RSI indicator.
- Cipla hits 15% upper circuit as USFDA gives final approval to Albuterol Inhalation AerosolFollowing the development, the scrip hit its 15 per cent upper circuit limit at Rs 589.95.
- Cipla gets final approval from USFDA for Albuterol Sulfate Inhalation AerosolIn a regulatory filing the company said "it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfa...
- Sun, Dr Reddy's among 7 Indian pharma majors sued in US for price riggingThe lawsuit widens a complaint of price collusion filed in 2016, which is still pending in US courts after being first investigated in 2014.
- Lupin gets EIR from USFDA for Pithampur facility unitLupin's Pithampur facility manufactures dermatological products, dry product inhalers, and metered dose inhalers.
- Taro drug pricing probe may widen to other generic drug makersResearch by IIFL shows several generic drug companies, including a few top Indian generic drug makers, effected steep price increases withi...
- Teva bid for Mylan sparks worries of rising generic drug pricesThe increase in generic-drug prices has been a growing concern across the pharmacy industry, affecting mom-and-pop businesses and giant cha...
- Local cos line up for Merck unitThe bidding process for the generics business of German pharmaceutical corporation Merck is set to begin in a few days. The advisors to Mer...
Load More
